ArticleNano today2014
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.
Article in Nano today, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 421 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
421 citing papers in PubMed, 1,218 citations in OpenAlex.
- Modelling nano-particle-PEG-NLS complexes for nucleus-targeted drug delivery: revisiting the multi-dynein nano-cargo transport on microtubules.Drug delivery · 2026Article
- New approach methodologies in nanomedicine: bridging the gap betweenChemical Society reviews · 2026Review
- Extracellular Vesicles: Classification, Biological Functions, Diseases, and Therapeutic Opportunities.MedComm · 2026Review
- The mitophagy targeted nano-assemblies with high Salvianolic acid B -loading sufficiently enhances osteoarthritis therapy.Materials today. Bio · 2026Article
- Exploring the impact of nutrition and autophagy on infectious diseases to inform the development of homeostatic-nanomedicines for HIV-TB coinfections.Discover nano · 2026Review
- Nanoparticle-Hydrogel Composites for Precision Medicine.Cell biomaterials · 2026Article
- Critical chemistry manufacturing and controls considerations for mRNA lipid nanoparticle translation.Discover nano · 2026Review
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Phase-change perfluorocarbon nanodroplets enable spatiotemporal control of ultrasound and photoacoustic imaging and therapy.Biomedical engineering letters · 2026Review
- Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy.Discover nano · 2026Review
- Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets.Nature communications · 2026Article
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Cell surface thiol-disulfide regulation in cancer: Mechanisms, implications, and theranostic strategies.Redox biology · 2026Review
- Phage Therapy in Gastrointestinal Diseases: Current Status and Challenges.International journal of molecular sciences · 2026Review
- Incubation of brain organoids with fluorescent carbon nanodots.RSC advances · 2026Article
- Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.Archives of microbiology · 2026Review
- Nanoparticles-based phototherapy systems: molecular mechanisms and clinical applications.Signal transduction and targeted therapy · 2026Review
- Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The lung-brain axis: elucidating the mechanisms of pulmonary-driven neurological disorders.Journal of neuroinflammation · 2026Review
- Inflamed vessel-anchored release of HScience advances · 2026Article
361 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticles (NPs) have emerged as an effective modality for the treatment of various diseases including cancer, cardiovascular and inflammatory diseases. Various forms of NPs including liposomes, polymer particles, micelles, dendrimers, quantum dots, gold NPs and carbon nanotubes have been synthesized and tested for therapeutic applications. One of the greatest challenges that limit the success of NPs is their ability to reach the therapeutic site at necessary doses while minimizing accumulation at undesired sites. The biodistribution of NPs is determined by body's biological barriers that manifest in several distinct ways. For intravascular delivery of NPs, the barrier manifests in the form of: (i) immune clearance in the liver and spleen, (ii) permeation across the endothelium into target tissues, (iii) penetration through the tissue interstitium, (iv) endocytosis in target cells, (v) diffusion through cytoplasm and (vi) eventually entry into the nucleus, if required. Certain applications of NPs also rely on delivery through alternate routes including skin and mucosal membranes of the nose, lungs, intestine and vagina. In these cases, the diffusive resistance of these tissues poses a significant barrier to delivery. This review focuses on the current understanding of penetration of NPs through biological barriers. Emphasis is placed on transport barriers and not immunological barriers. The review also discusses design strategies for overcoming the barrier properties.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.